Similar articles

• Bevacizumab: a new way of doing business?

  Canning C, Lotery A. Canning C, et al. Eye (Lond). 2006 Sep;20(9):985-7. doi: 10.1038/sj.eye.6702501. Epub 2006 Jul 21. Eye (Lond). 2006. PMID: 16858443 Review.
• A very effective treatment for neovascular macular degeneration.

  Stone EM. Stone EM. N Engl J Med. 2006 Oct 5;355(14):1493-5. doi: 10.1056/NEJMe068191. N Engl J Med. 2006. PMID: 17021326 No abstract available.
• Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.

  El-Mollayess GM, Noureddine BN, Bashshur ZF. El-Mollayess GM, et al. Semin Ophthalmol. 2011 May;26(3):69-76. doi: 10.3109/08820538.2010.545100. Semin Ophthalmol. 2011. PMID: 21609219 Review.
• Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.

  Ziemssen F, Heiduschka P, Schraermeyer U; Tübingen Bevacizumab Study Group. Ziemssen F, et al. Retina. 2007 Oct;27(8):1154-6; author reply 1156-8. doi: 10.1097/IAE.0b013e3180ca7daf. Retina. 2007. PMID: 18040264 No abstract available.
• Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.

  Schmucker C, Antes G, Lelgemann M. Schmucker C, et al. Surv Ophthalmol. 2009 Nov-Dec;54(6):705-7. doi: 10.1016/j.survophthal.2009.08.002. Surv Ophthalmol. 2009. PMID: 19818262 Review. No abstract available.